Aficamten is a clinical-stage drug being developed for the treatment of Obstructive hypertrophic cardiomyopathy (oHCM) is a genetic cardiac disorder characterized by abnormal thickening of the left ventricular myocardium that results in dynamic obstruction of the left ventricular outflow tract. It affects approximately 3-10 in 10,000 individuals in US (1), though many remain undiagnosed, making it one of the most common inherited cardiovascular diseases. This condition places a heavy burden on patients, increasing the risk of heart failure, irregular heart rhythms, stroke, and even sudden death. It can also severely affect daily life, causing shortness of breath with activity, chest discomfort, and fainting spells. oHCM arises from mutations in heart-muscle proteins. These changes make the heart squeeze too strongly and relax poorly. Over time, the heart muscle becomes thickened and disorganized, and the thickened tissue can block blood leaving the heart. This blockage raises pressure inside the heart and leads to many of the symptoms patients experience.. It is being developed by Cytokinetics, Incorporated. The FDA Prescription Drug User Fee Act (PDUFA) date is December 25, 2025. Premium analysis including detailed clinical trial status, revenue predictions, and comprehensive company insights are available for members.